ArticleCancer research2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups.Endocrine pathology · 2026Article
- Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.The Journal of clinical investigation · 2026Article
- Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.The Journal of clinical investigation · 2026Article
- The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.Molecular biomedicine · 2026Review
- Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer.Journal of the National Cancer Center · 2026Review
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Jumonji domain-containing 6 promotes the expansion of neuroblastoma stem cells by activating the wingless/ integrated pathway.CytoJournal · 2026Article
- Integrative analysis of non-small cell lung cancer identifies Jumonji domain-containing 6/ETS homologous factor axis as a target to overcome radioresistance.Signal transduction and targeted therapy · 2025Article
- Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 (IGF2BP2) Promotes Castration-Resistant Prostate Cancer Progression by Regulating AR-V7 mRNA Stability.Cancer reports (Hoboken, N.J.) · 2025Article
- Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.Molecular therapy. Oncology · 2024Article
- Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.Molecular cancer research : MCR · 2024Article
- SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer.Science advances · 2024Article
- Dichotomous intronic polyadenylation profiles reveal multifaceted gene functions in the pan-cancer transcriptome.Experimental & molecular medicine · 2024Article
- Versatile JMJD proteins: juggling histones and much more.Trends in biochemical sciences · 2024Review
- The emerging roles of histone demethylases in cancers.Cancer metastasis reviews · 2024Review
- Article
- The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer.The Journal of clinical investigation · 2023Article
- JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis.Oncogene · 2023Article
- Elucidating the role of PRMTs in prostate cancer using open access databases and a patient cohort dataset.Histology and histopathology · 2023Article
- Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 6 institutions in 5 countries.
Alec Paschalis *The Institute of Cancer Research, London, United Kingdom.
Jonathan Welti *The Institute of Cancer Research, London, United Kingdom.
Antje J NeebThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-6516-2938
Wei YuanThe Institute of Cancer Research, London, United Kingdom.
Ines FigueiredoThe Institute of Cancer Research, London, United Kingdom.
Rita PereiraThe Institute of Cancer Research, London, United Kingdom.
Ana FerreiraThe Institute of Cancer Research, London, United Kingdom.
Ruth RiisnaesThe Institute of Cancer Research, London, United Kingdom.
Daniel Nava RodriguesThe Institute of Cancer Research, London, United Kingdom.
Juan M Jiménez-VacasMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain.
Soojin KimDepartment of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, Washington.
Takuma UoDepartment of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, Washington.
Patrizio Di MiccoThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-2242-6294
Anthony TumberChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.
Md Saiful IslamChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.
Marc A MoesserChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0001-9882-3272
Martine AbboudChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0003-2141-5988
Akane KawamuraChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.
Bora GurelThe Institute of Cancer Research, London, United Kingdom.
Rossitza ChristovaThe Institute of Cancer Research, London, United Kingdom.
Veronica S GilThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-4562-869X
Lorenzo BuroniThe Institute of Cancer Research, London, United Kingdom.
Mateus CrespoThe Institute of Cancer Research, London, United Kingdom.
Susana MirandaThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-5936-2706
Maryou B LambrosThe Institute of Cancer Research, London, United Kingdom.
Suzanne CarreiraThe Institute of Cancer Research, London, United Kingdom.
Nina TunariuThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0001-6656-3699
Andrea AlimontiORCID https://orcid.org/0000-0002-9362-2313
Bissan Al-LazikaniThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0003-3367-2519
Christopher J SchofieldChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.
Stephen R PlymateDepartment of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, Washington.
Adam Sharp *The Institute of Cancer Research, London, United Kingdom.
Johann S de Bono *The Institute of Cancer Research, London, United Kingdom. johann.de-bono@icr.ac.uk.ORCID https://orcid.org/0000-0002-2034-595X
, SU2C/PCF International Prostate Cancer Dream Team
Institute of Cancer Research · GBUniversity of Oxford · GBRoyal Marsden NHS Foundation Trust · GBUniversity of Washington · USInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversity of Padua · IT
Funding
Tissue and Pathology CoreU54CA126540 · NCI · UNIVERSITY OF WASHINGTON · PI CAMPISI, JUDITH · 2006 to 2010
$3.3MTargeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate CancerI01BX003324 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2016 to 2024
–BLRD VA I01 BX003324Cancer Research UK 18245Cancer Research UK 28285Cancer Research UK C8717/A18245European Research Council 683136Medical Research Council MR/M018318/1NCI NIH HHS U54 CA126540Prostate Cancer UK CEO13_2-002Wellcome Trust 106244/Z/14/Z
Abstract
Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, we determined proteins key to generating AR-V7, validated our findings using clinical samples, and studied splicing regulatory mechanisms in prostate cancer models. Triangulation studies identified JMJD6 as a key regulator of AR-V7, as evidenced by its upregulation with
Indexed as
Alternative SplicingAntineoplastic AgentsCell Line, TumorCohort StudiesEnzyme InhibitorsGene Expression Regulation, NeoplasticHumansJumonji Domain-Containing Histone DemethylasesMaleMolecular Targeted TherapyOxygenasesPrognosisProstatic Neoplasms, Castration-ResistantProtein IsoformsReceptors, AndrogenRetrospective StudiesAntineoplastic AgentsAR protein, humanEnzyme InhibitorsJMJD6 protein, humanJumonji Domain-Containing Histone DemethylasesOxygenasesProtein IsoformsReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.